Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ezekowitz

Showing results (631-640 of 842) with videos related to

Pageof 85
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy|February 19, 2021
Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trialAmy A Kirkham, Edith Pituskin, Richard B Thompson, et al.
Nature|December 8, 2006
A systems biology analysis of the Drosophila phagosomeL M Stuart, J Boulais, G M Charriere, et al.
Trials|February 6, 2021
Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trialMona Aflaki, Alexandria Flannery, João Pedro Ferreira, et al.
ESC Heart Failure|September 27, 2021
Cardiac remodelling predicts outcome in patients with chronic heart failureLingyu Xu, Joseph Pagano, Kelvin Chow, et al.
ESC Heart Failure|November 16, 2021
The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trialJustin A Ezekowitz, Wendimagegn Alemayehu, Sarah Rathwell, et al.
ESC Heart Failure|January 20, 2025
Relaxin mimetic in pulmonary hypertension associated with left heart disease: Design and rationale of Re-PHIREMarcin Ufnal, Kathleen Connolly, Marcus Millegard, et al.
JACC. Heart Failure|September 1, 2022
Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of VericiguatPaul W Armstrong, Yinggan Zheng, Richard W Troughton, et al.
JAMA Network Open|September 16, 2020
Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY TrialsZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
European Journal of Heart Failure|September 12, 2015
Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysisJoanne Simpson, Davide Castagno, Rob N Doughty, et al.
Journal of Cardiac Failure|January 31, 2025
Prediction and Longer-Term Outcomes of All-cause and Cardiovascular Mortality in the HEART-FID TrialJustin A Ezekowitz, Hillary Mulder, Robert J Mentz, et al.
Pageof 85

Showing results (631-640 of 842) with videos related to

Sort By:
Pageof 85
European Heart Journal. Cardiovascular Pharmacotherapy|February 19, 2021
Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trialAmy A Kirkham, Edith Pituskin, Richard B Thompson, et al.
Nature|December 8, 2006
A systems biology analysis of the Drosophila phagosomeL M Stuart, J Boulais, G M Charriere, et al.
Trials|February 6, 2021
Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trialMona Aflaki, Alexandria Flannery, João Pedro Ferreira, et al.
ESC Heart Failure|September 27, 2021
Cardiac remodelling predicts outcome in patients with chronic heart failureLingyu Xu, Joseph Pagano, Kelvin Chow, et al.
ESC Heart Failure|November 16, 2021
The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trialJustin A Ezekowitz, Wendimagegn Alemayehu, Sarah Rathwell, et al.
ESC Heart Failure|January 20, 2025
Relaxin mimetic in pulmonary hypertension associated with left heart disease: Design and rationale of Re-PHIREMarcin Ufnal, Kathleen Connolly, Marcus Millegard, et al.
JACC. Heart Failure|September 1, 2022
Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of VericiguatPaul W Armstrong, Yinggan Zheng, Richard W Troughton, et al.
JAMA Network Open|September 16, 2020
Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY TrialsZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
European Journal of Heart Failure|September 12, 2015
Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysisJoanne Simpson, Davide Castagno, Rob N Doughty, et al.
Journal of Cardiac Failure|January 31, 2025
Prediction and Longer-Term Outcomes of All-cause and Cardiovascular Mortality in the HEART-FID TrialJustin A Ezekowitz, Hillary Mulder, Robert J Mentz, et al.
Pageof 85